EMD Group (EMD Serono, Inc. (Rockland)) Establishes Immuno-Oncology Research and Early Development Platform to Advance Innovation in Cancer Therapies
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
ROCKLAND, Mass.--(BUSINESS WIRE)--EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today its commitment to the field of cancer immunotherapy by creating a fully dedicated immuno-oncology innovation platform integrating research, early development and biomarker strategies. In addition to the company’s existing oncology platform, this new immuno-oncology platform will focus on developing therapies that leverage the immune system’s natural ability to fight tumors, and work in combination with existing and future therapies.
Help employers find you! Check out all the jobs and post your resume.
ROCKLAND, Mass.--(BUSINESS WIRE)--EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today its commitment to the field of cancer immunotherapy by creating a fully dedicated immuno-oncology innovation platform integrating research, early development and biomarker strategies. In addition to the company’s existing oncology platform, this new immuno-oncology platform will focus on developing therapies that leverage the immune system’s natural ability to fight tumors, and work in combination with existing and future therapies.
Help employers find you! Check out all the jobs and post your resume.